Key result
In spontaneously hypertensive rats, 12 weeks of treatment with L-158,809 reduced systolic blood pressure in a dose-dependent manner from 206 mmHg in controls to 154 mmHg at 0.6 mg/kg.
Why the study?
Does the angiotensin type 1 receptor antagonist L-158,809 reduce blood pressure and vascular structural changes in spontaneously hypertensive rats?
Population
15-week-old male spontaneously hypertensive rats (SHR)
Comparison
Angiotensin type 1 receptor antagonist L-158,809… vs Untreated control spontaneously hypertensive rats
Design
Preclinical
Follow-up
12 weeks of treatment, followed by 14-16 weeks of withdrawal
Authors
Loading...
AT1 blockade improves BP and vascular structure in adult SHR; leaves open translation to human hypertension.
Does the angiotensin type 1 receptor antagonist L-158,809 reduce blood pressure and vascular structural changes in spontaneously hypertensive rats?
Absolute Event Rate: 154% vs 206%
Chronic blockade of angiotensin II type 1 receptors with L-158,809 dose-dependently reduces blood pressure and improves arterial structure in spontaneously hypertensive rats.
Gillies et al. (1996) studied Hypertension. L-158,809 vs. untreated control SHR was evaluated on Average systolic blood pressure. In spontaneously hypertensive rats, 12 weeks of treatment with L-158,809 reduced systolic blood pressure in a dose-dependent manner from 206 mmHg in controls to 154 mmHg at 0.6 mg/kg.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: